Neuroprotective Potential of Saroglitazar Against Cerebral Ischemia/Reperfusion Injury in Sprague–Dawley Rats: Targeting HMGB-1/NF-κB Pathway
ASSAY and Drug Development Technologies · 2026
DOI: 10.1089/adt.2025.057 ↗Kurz gefasst
Fachartikel in der Zeitschrift ASSAY and Drug Development Technologies, 2026. Verfasst von Prachi Mistry und 4 weiteren Autor:innen. Beteiligte Einrichtung: L.J. Institute of Pharmacy, L J University, Ahmedabad, India. Hauptthemen laut MEDLINE: Reperfusion Injury, NF-kappa B, Neuroprotective Agents, HMGB1 Protein. Die Arbeit nennt 74 Literaturangaben.
Abstract (Originalsprache)
Stroke is an intricate oxidative and inflammatory response resulting from cerebral ischemia followed by reperfusion injury. Complex pathophysiology of stroke poses challenges for treatment. Peroxisome proliferator-activated receptor (PPAR) expression in the rat hippocampus is markedly elevated post cerebral ischemia/reperfusion (I/R) injury. Hence, saroglitazar, a dual PPAR-α/γ agonist, was investigated against cerebral I/R injury in rats. Male Sprague–Dawley rats were subjected to bilateral common carotid artery occlusion for 30 min and reperfusion for 3 days. During the reperfusion, animals were treated with vehicle or saroglitazar once a day for 3 days. The behavioral parameters were assessed, and animals were sacrificed to measure oxidative markers (malondialdehyde, superoxide dismutase, catalase, and reduced glutathione), inflammatory markers (interleukin-6, tumor necrosis factor-α, nuclear factor kappa-light chain enhancer of activated B cells (NF-κB), and high mobility group box 1 (HMGB-1) protein, infarction, and histopathology changes. Following I/R injury, antioxidant enzymes were reduced, while nitric oxide and inflammatory markers were increased in the disease group. In the rat hippocampus, these changes led to neurobehavioral impairment and cerebral infarction. Saroglitazar improved the levels of antioxidants and reduced inflammation; 2,3,5-triphenyltetrazolium chloride stain and histopathological analysis revealed the neuroprotective effect of saroglitazar in the hippocampus region. The neuroprotective effects of saroglitazar were attributed to its activation of both PPAR-α and PPAR-γ. It improved antioxidant levels and inhibited proinflammatory cytokines by suppressing the HMGB-1/NF-κB signaling pathway. These findings underscore the potential of saroglitazar in mitigating cerebral I/R injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- L.J. Institute of Pharmacy, L J University, Ahmedabad, India.
- Department of Pharmacology, Parul Institute of Pharmacy, Parul University, Waghodia, India.
- School of Pharmacy, National Forensic Sciences University, Gandhinagar, India.
ORCID-Profile: Vijay Kevlani
Zitieren
APA
Mistry, P., Prajapati, S., Vadher, P., Soni, J., & Kevlani, V. (2026). Neuroprotective Potential of Saroglitazar Against Cerebral Ischemia/Reperfusion Injury in Sprague–Dawley Rats: Targeting HMGB-1/NF-κB Pathway. ASSAY and Drug Development Technologies. https://doi.org/10.1089/adt.2025.057
Vancouver
Mistry P, Prajapati S, Vadher P, Soni J, Kevlani V. Neuroprotective Potential of Saroglitazar Against Cerebral Ischemia/Reperfusion Injury in Sprague–Dawley Rats: Targeting HMGB-1/NF-κB Pathway. ASSAY and Drug Development Technologies. 2026. doi:10.1089/adt.2025.057
BibTeX
@article{Mistry2026,
author = {Mistry, Prachi and Prajapati, Sanjiv and Vadher, Paridhi and Soni, Jhanvi and Kevlani, Vijay},
title = {Neuroprotective Potential of Saroglitazar Against Cerebral Ischemia/Reperfusion Injury in Sprague–Dawley Rats: Targeting HMGB-1/NF-κB Pathway},
journal = {ASSAY and Drug Development Technologies},
year = {2026},
doi = {10.1089/adt.2025.057}
}
EUVIMED